

# Eastar™ copolyester 6763

## Accelerated aging in medical packaging

Medical device manufacturers currently require packaging materials to provide microbial barrier and device protection that lasts for an extended period of time. For example, devices may need protection for up to 5 years. Package material aging information is needed to ensure package integrity, satisfy current FDA validation requirements, and provide evidence of sterility and fitness for use over a product's life cycle. To decrease the time required for testing prior to device commercialization, manufacturers perform accelerated-aging studies on the product/package combination. An important aspect of the aging of plastics is physical aging. The physical properties of plastics can improve or deteriorate over time as a plastic is held below its glass transition temperature ( $T_g$ ). It is important that accelerated-aging studies be performed properly since each plastic material ages differently. This technical tip will provide guidelines for the proper aging of Eastar™ copolyester 6763.

### General accelerated-physical-aging guidelines

- The ASTM F1980 standard guidelines or methodology for accelerated aging of sterile medical device packages is based on the following Arrhenius equation:

$$t_E = t_T * Q_{10}^{a(T-T_{RT})/10}$$

Where

$t_E$  = Equivalent time at ambient temperature and 50% relative humidity

$t_T$  = Accelerated-aging time

$T$  = Accelerated-aging temperature, °C

$T_{RT}$  = Ambient temperature, 23°C

$Q_{10}$  = Accelerated-aging factor

<sup>a</sup> The ASTM guidelines suggest using a  $Q_{10}$  factor of 2 as a conservative estimate for aging the packaging and device. The guidelines also state that each material has a unique accelerated-aging factor ( $Q_{10}$ ). Other  $Q_{10}$  factors can be used if they are derived from experimentation. Eastman has found through extensive experimentation that the  $Q_{10}$  factor for Eastar copolyesters is 9.8.

- Recommended conditions for Eastar copolyesters: Perform aging at 50°C and 50% relative humidity. At these conditions, 18 hours is equivalent to 1 year of actual aging at room temperature (23°C). Therefore, 92 hours of aging at accelerated conditions is equivalent to 5 years of actual aging at room temperature (23°C).
- Plastic material aging is reset, or returns to a zero age, during thermoforming.

### Detailed description of accelerated physical aging

Physical aging is a process of molecular relaxation that occurs in all amorphous polymers held at temperatures below their  $T_g$ . It has been observed in PVC, polystyrene, styrene-acrylonitrile (SAN), and polycarbonate, as well as in copolyesters. When a polymer is rapidly cooled to below its  $T_g$  (as occurs with all commercial melt-phase processing techniques), it freezes into a nonequilibrium conformation with excess free volume. In an attempt to attain thermodynamic equilibrium, the chains rearrange themselves into a more dense structure, reducing the free volume of the system. Although this densification is difficult to detect, it directly affects other thermodynamic and mechanical properties which are easier to measure and can be used to track the extent of aging with time.

In general, these properties increase in linear fashion with the log of aging time. Aging also proceeds more quickly at higher temperatures closer to the material's  $T_g$ . These trends are consistent with other similar viscoelastic molecular relaxation processes, such as rheological behavior. As with other relaxation processes, time and temperature can relate through the principle of time-temperature superposition. According to this principle, molecular motions that occur over a given period of time at one temperature are equivalent to motions that occur over a longer period of time at lower temperatures. In other words, an elevated temperature acts as a multiplier for the rate of motion. Because of time-temperature superposition, it is possible to generate data as a function of time at different temperatures and then shift the data together on one common master curve.

Numerous experiments were performed at Eastman to determine the mechanical and thermal properties of our copolyesters as a function of aging time and temperature. Time-temperature superpositions were performed on the data generated from these experiments to create master curves for each material. Aging times at each aging temperature that provided equivalent material properties were recorded. These times and temperatures, shown in the table, can be used to perform accelerated-aging experiments. A part is aged at an elevated temperature for a short period of time to simulate aging at a lower temperature for an extended period of time. For example, 1 hour at 60°C is equivalent to 110 hours at 40°C or 5,040 hours at 23°C. Likewise, 1 hour at 40°C equals 48 hours at 23°C. Therefore, if one wanted to simulate the performance of a part after 10 years of life (87,600 hours) at 23°C, one should age the part at either 50°C for 185 hours or 60°C for 19 hours. This aging protocol will reasonably represent the lifetime of a typical copolyester application. Note that aging copolyesters at higher temperatures for longer periods of time is not generally recommended. For example, aging for 250 hours (10 days) at 60°C is equivalent to aging for 1,200,000 hours (133 years) at room temperature (23°C). Aging for this length of time or longer at 60°C may overage the material and provide an unrealistic expectation of what the properties would be after aging at room temperature.

## Accelerated age testing of Eastar™ copolyester 6763

Eastman has performed accelerated aging on Eastar™ copolyester 6763 using these guidelines and methodology. The data generated suggests that Eastar 6763 provides the required package integrity for a minimum of 5 years if good manufacturing practices are followed during extrusion, forming, package design, and sterilization—and the packaging is stored at room temperature under normal conditions.

### Accelerated-physical-aging data

Aging temperature	Simulated age/accelerated aging time (hours)						
	~165 years	~17 years	~20 months	~12 months	~7 months	~3 weeks	~2 days
23°C (74°F)	1,400,000	150,000	15,000	8,800	5,100	500	48
30°C (86°F)	290,000	30,000	3,000	1,800	1,000	100	10
40°C (104°F)	30,000	3,100	300	180	110	10	1.0
50°C (122°F)	3,000	310	31	18	11	1.0	—
60°C (140°F)	310	32	3.1	1.9	1.1	—	—
65°C (150°F)	99	10	1.0	0.6	—	—	—

# EASTMAN

The results of insight™

## Eastman Chemical Company Corporate Headquarters

P.O. Box 431  
Kingsport, TN 37662-5280 U.S.A.

U.S.A. and Canada, 800-EASTMAN (800-327-8626)  
Other Locations, +(1) 423-229-2000

[www.eastman.com/locations](http://www.eastman.com/locations)

Safety Data Sheets providing safety precautions that should be observed when handling and storing Eastman products are available online or by request. You should obtain and review the available material safety information before handling any of these products. If any materials mentioned are not Eastman products, appropriate industrial hygiene and other safety precautions recommended by their manufacturers should be observed.

*It is the responsibility of the medical device manufacturer ("Manufacturer") to determine the suitability of all component parts and raw materials, including any Eastman product, used in its final product to ensure safety and compliance with requirements of the United States Food and Drug Administration (FDA) or other international regulatory agencies.*

*Eastman products have not been designed for nor are they promoted for end uses that would be categorized either by the United States FDA or by the International Standards Organization (ISO) as implant devices. Eastman products are not intended for use in the following applications: (1) in any bodily implant applications for greater than 30 days, based on FDA-Modified ISO-10993, Part 1, "Biological Evaluation of Medical Devices" tests (including any cosmetic, reconstructive, or reproductive implant applications); (2) in any cardiac prosthetic device application, regardless of the length of time involved, including, without limitation, pacemaker leads and devices, artificial hearts, heart valves, intra-aortic balloons and control systems, and ventricular bypass assisted devices; or (3) as any critical component in any medical device that supports or sustains human life.*

*For manufacturers of medical devices, biological evaluation of medical devices is performed to determine the potential toxicity resulting from contact of the component materials of the device with the body. The ranges of tests under FDA-Modified ISO-10993, Part 1, "Biological Evaluation of Medical Devices" include cytotoxicity, sensitization, irritation or intracutaneous reactivity, systemic toxicity (acute), subchronic toxicity (subacute), implantation, and hemocompatibility. For Eastman products offered for the medical market, limited testing information is available on request. The Manufacturer of the medical device is responsible for the biological evaluation of the finished medical device.*

*The suitability of an Eastman product in a given end-use environment is dependent on various conditions including, without limitation, chemical compatibility, temperature, part design, sterilization method, residual stresses, and external loads. It is the responsibility of the Manufacturer to evaluate its final product under actual end-use requirements and to adequately advise and warn purchasers and users thereof.*

© 2016 Eastman Chemical Company. Eastman brands referenced herein are trademarks of Eastman Chemical Company or one of its subsidiaries or are being used under license. The ® symbol denotes registered trademark status in the U.S.; marks may also be registered internationally. Non-Eastman brands referenced herein are trademarks of their respective owners.